Monopteros Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Monopteros Therapeutics Inc. - overview
Established
2019
Location
-, MA, US
Primary Industry
Pharmaceuticals
About
Based in Massachusetts, US, and founded in 2019, Monopteros Therapeutics Inc. operates as a pharmaceutical research company that reprograms regulatory T cells (“Tregs”) for cancer immunotherapy resistance. The company was co-founded by Thorsten Mempel, MD, Ph. D.
, and Ulrich von Andrian, MD. In 2021, the company raised USD 20 million in series A funding from Medicxi. Monopteros Therapeutics Inc. 's research team develops MPT-0118 that undergo a dose escalation and cohort expansion clinical trial.
The MPT-0118 is provided as a tablet formulation for oral dosing in its Phase 1/1b clinical trial.
Current Investors
Medicxi
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.monopterostx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.